Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|February 27, 2014
FDA Reports Recalls Due to Broken Tablets
Author(s)Pharmaceutical Technology Editors
Discovery of split and broken tablets led to drug recalls.
Advertisement
FDA reported recent recalls of prescription drugs due to broken or split tablets in an enforcement report. The recalls were voluntarily initiated by the manufacturers and involved prescription products only.
One lot (lot #JKM7075A) of oxcarbazepine tablets (300 mg, 100 tablet bottles) distributed by Caraco Pharmaceutical Laboratories (Detroit, MI) and manufactured by Sun Pharmaceutical (India) was recalled. The recall was initiated after investigation into complaints found the potential for this lot to contain broken tablets, according to the recall notice.
In addition, bottles from lot# 605957A of diclofenac sodium and misoprostol delayed-release tablets (75 mg/0.2 mg, 60-count bottle) manufactured by Watson Laboratories, now Actavis (Corona, CA), were voluntarily recalled. The recall was initiated because split tablets were found in the 12-month stability samples.
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement